Takeda Pharmaceutical Company Limited(TAK)Earnings, Financials & Key Ratios
TAK•NYSE
$16.72
$52.82B mkt cap·77.7× P/E·Price updated May 6, 2026
AboutTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.Show more
- Revenue$4581.55B+7.5%
- EBITDA$1103.98B+28.6%
- Net Income$107.93B-25.1%
- EPS (Diluted)33.62-26.2%
- Gross Margin65.51%-1.4%
- EBITDA Margin24.1%+19.7%
- Operating Margin7.48%+48.9%
- Net Margin2.36%-30.3%
- ROE1.52%-28.2%
- ROIC2.26%+54.0%
- Debt/Equity0.65-2.2%
- Interest Coverage2.49-98.8%
TAK Key Insights
Takeda Pharmaceutical Company Limited (TAK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 19.5%
- ✓FCF machine: 18.7% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 3.6%
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak 3Y average ROE of 3.0%
- ✗Dividend payout exceeds 100% of earnings
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TAK Price & Volume
Takeda Pharmaceutical Company Limited (TAK) stock price & volume — 10-year historical chart
Loading chart...
TAK Growth Metrics
Takeda Pharmaceutical Company Limited (TAK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.93%
5 Years6.84%
3 Years8.68%
TTM-2.03%
Profit CAGR
10 Years-
5 Years19.53%
3 Years-22.3%
TTM-44.85%
EPS CAGR
10 Years-
5 Years18.93%
3 Years-22.75%
TTM-45.2%
Return on Capital
10 Years3.85%
5 Years3.55%
3 Years2.97%
Last Year2.79%
TAK Recent Earnings
Takeda Pharmaceutical Company Limited (TAK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (64%)●Beat Revenue 9/12 qtrs (82%)
Q1 2026Latest
Jan 29, 2026EPS
$0.48
Est $0.55
-12.7%
Revenue
$7.7B
Est $7.5B
+2.5%
Q4 2025
Oct 30, 2025EPS
$0.44
Est $0.44
+0.0%
Revenue
$7.4B
Est $7.5B
-0.9%
Q3 2025
Jul 30, 2025EPS
$0.52
Est $0.47
+10.6%
Revenue
$7.6B
Est $8.0B
-3.9%
Q3 2025
Jun 25, 2025EPS
$0.22
Revenue
$7.2B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Jan 29, 2026 | $0.48vs $0.55-12.7% | $7.7Bvs $7.5B+2.5% |
| Q4 2025 | Oct 30, 2025 | $0.44vs $0.44+0.0% | $7.4Bvs $7.5B-0.9% |
| Q3 2025 | Jul 30, 2025 | $0.52vs $0.47+10.6% | $7.6Bvs $8.0B-3.9% |
| Q3 2025 | Jun 25, 2025 | $0.22 | $7.2B |
Based on last 12 quarters of dataView full earnings history →
TAK Peer Comparison
Takeda Pharmaceutical Company Limited (TAK) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVO | 203.36B | 45.76 | 12.65 | 6.43% | 33.14% | 61.1% | 0.67 | |
 AZN | 286.68B | 184.92 | 28.28 | 8.63% | 17.19% | 22.24% | 0.61 | |
 SNY | 105.71B | 43.77 | 18.37 | 5.49% | 16.72% | 10.78% | 0.30 | |
 NVS | 283.08B | 148.36 | 20.63 | 5.97% | 24.14% | 31.42% | 0.80 | |
 GSK | 101.62B | 50.53 | 6.69 | 4.11% | 19.19% | 31.48% | 1.11 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 BMY | 115.43B | 56.54 | 16.39 | -0.22% | 15.01% | 38.96% | 2.55 | |
 JNJ | 541.31B | 224.62 | 38.79 | 4.3% | 27.26% | 31.69% | 0.51 |
Compare TAK vs Peers
Takeda Pharmaceutical Company Limited (TAK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TAK Income Statement
Takeda Pharmaceutical Company Limited (TAK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.73T | 1.77T | 2.1T | 3.29T | 3.2T | 3.57T | 4.03T | 4.26T | 4.58T | 4.49T |
| Revenue Growth % | -4.17% | 2.22% | 18.45% | 56.93% | -2.84% | 11.61% | 12.85% | 5.87% | 7.45% | -2.03% |
| Cost of Goods Sold | 558.75B | 495.92B | 659.69B | 1.09T | 994.31B | 1.11T | 1.24T | 1.43T | 1.58T | 1.7T |
| COGS % of Revenue | 32.26% | 28.01% | 31.46% | 33.11% | 31.09% | 31.01% | 30.89% | 33.57% | 34.49% | - |
| Gross Profit | 1.17T▲ 0% | 1.27T▲ 8.6% | 1.44T▲ 12.8% | 2.2T▲ 53.1% | 2.2T▲ 0.1% | 2.46T▲ 11.7% | 2.78T▲ 13.0% | 2.83T▲ 1.8% | 3T▲ 6.0% | 2.79T▲ 0% |
| Gross Margin % | 67.74% | 71.99% | 68.54% | 66.89% | 68.91% | 68.99% | 69.11% | 66.43% | 65.51% | 62.11% |
| Gross Profit Growth % | -7.76% | 8.63% | 12.78% | 53.14% | 0.09% | 11.74% | 13.05% | 1.76% | 5.97% | - |
| Operating Expenses | 1.02T | 1.03T | 1.28T | 2.1T | 1.69T | 2T | 2.29T | 2.62T | 2.66T | 2.41T |
| OpEx % of Revenue | 58.74% | 58.33% | 60.9% | 63.84% | 52.98% | 56.07% | 56.93% | 61.41% | 58.03% | - |
| Selling, General & Admin | 619.06B | 628.11B | 717.6B | 964.74B | 875.66B | 886.36B | 997.31B | 1.05T | 1.1T | 1.09T |
| SG&A % of Revenue | 35.74% | 35.48% | 34.22% | 29.31% | 27.38% | 24.83% | 24.76% | 24.72% | 24.11% | - |
| Research & Development | 312.3B | 325.44B | 368.3B | 492.38B | 455.83B | 526.09B | 633.33B | 729.92B | 730.23B | 699.77B |
| R&D % of Revenue | 18.03% | 18.38% | 17.56% | 14.96% | 14.25% | 14.74% | 15.73% | 17.12% | 15.94% | - |
| Other Operating Expenses | 705.13B | 707.38B | 908.87B | 643.9B | 362.74B | 588.87B | 662.27B | 834.44B | 823.75B | 3M |
| Operating Income | 155.87B▲ 0% | 241.79B▲ 55.1% | 204.97B▼ 15.2% | 100.41B▼ 51.0% | 509.27B▲ 407.2% | 460.84B▼ 9.5% | 490.5B▲ 6.4% | 214.07B▼ 56.4% | 342.59B▲ 60.0% | 372.72B▲ 0% |
| Operating Margin % | 9% | 13.66% | 9.77% | 3.05% | 15.93% | 12.91% | 12.18% | 5.02% | 7.48% | 8.31% |
| Operating Income Growth % | 19.14% | 55.13% | -15.23% | -51.01% | 407.2% | -9.51% | 6.44% | -56.36% | 60.03% | - |
| EBITDA | 327.29B | 423.92B | 452.66B | 684.06B | 1.07T | 1.04T | 1.15T | 858.54B | 1.1T | 1.14T |
| EBITDA Margin % | 18.9% | 23.94% | 21.58% | 20.78% | 33.43% | 29.25% | 28.68% | 20.14% | 24.1% | 25.49% |
| EBITDA Growth % | -0.28% | 29.52% | 6.78% | 51.12% | 56.26% | -2.33% | 10.62% | -25.66% | 28.59% | 5.64% |
| D&A (Non-Cash Add-back) | 171.43B | 182.13B | 247.69B | 583.65B | 559.67B | 583.15B | 664.4B | 644.46B | 761.4B | 770.64B |
| EBIT | 150.91B | 227.24B | 175.77B | 88.26B | 424.05B | 600.06B | 619.67B | 499.48B | 449.12B | 622.74B |
| Net Interest Income | -6.97B | -6.78B | -60.96B | -1.36B | -128.65B | -117.67B | -111.19B | -984.34M | -117.67B | -108.75B |
| Interest Income | 12.27B | 39.54B | 6.62B | 103.03M | 1.78B | 4.59B | 5.51B | 78.1M | 19.64B | 207.73B |
| Interest Expense | 23.25B | 31.93B | 48.16B | 1.46B | 130.81B | 122.43B | 116.97B | 1.06B | 137.31B | 316.48B |
| Other Income/Expense | -12.52B | -24.58B | -110.07B | -161.16B | -143.03B | -158.27B | -115.42B | -161.28B | -167.5B | -164.94B |
| Pretax Income | 143.35B▲ 0% | 217.21B▲ 51.5% | 94.9B▼ 56.3% | -60.75B▼ 164.0% | 366.24B▲ 702.8% | 302.57B▼ 17.4% | 375.09B▲ 24.0% | 52.79B▼ 85.9% | 175.08B▲ 231.7% | 207.78B▲ 0% |
| Pretax Margin % | 8.28% | 12.27% | 4.52% | -1.85% | 11.45% | 8.48% | 9.31% | 1.24% | 3.82% | 4.63% |
| Income Tax | 27.83B | 30.5B | -14.12B | -105.04B | -9.94B | 72.41B | 58.05B | -91.41B | 66.94B | 92.73B |
| Effective Tax Rate % | 19.42% | 14.04% | -14.88% | 172.9% | -2.71% | 23.93% | 15.48% | -173.15% | 38.23% | 44.63% |
| Net Income | 114.94B▲ 0% | 186.89B▲ 62.6% | 109.13B▼ 41.6% | 44.24B▼ 59.5% | 376B▲ 749.9% | 230.06B▼ 38.8% | 317.02B▲ 37.8% | 144.07B▼ 54.6% | 107.93B▼ 25.1% | 114.75B▲ 0% |
| Net Margin % | 6.64% | 10.56% | 5.2% | 1.34% | 11.76% | 6.45% | 7.87% | 3.38% | 2.36% | 2.56% |
| Net Income Growth % | 43.38% | 62.59% | -41.61% | -59.46% | 749.9% | -38.81% | 37.8% | -54.56% | -25.08% | -44.85% |
| Net Income (Continuing) | 115.51B | 186.71B | 135.08B | 44.29B | 376.17B | 230.17B | 317.04B | 144.2B | 108.14B | 115.06B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 54.7B | 19.98B | 4.01B | 4B | 4.14B | 504M | 549M | 741M | 895M | 1.15B |
| EPS (Diluted) | 73.13▲ 0% | 118.78▲ 62.4% | 34.78▼ 70.7% | 14.13▼ 59.4% | 119.48▲ 745.6% | 72.94▼ 39.0% | 100.97▲ 38.4% | 45.58▼ 54.9% | 33.62▼ 26.2% | 35.80▲ 0% |
| EPS Growth % | 43.79% | 62.42% | -70.72% | -59.37% | 745.58% | -38.95% | 38.43% | -54.86% | -26.24% | -45.2% |
| EPS (Basic) | 73.58 | 119.68 | 34.78 | 14.21 | 120.36 | 73.57 | 102.15 | 46.05 | 34.17 | - |
| Diluted Shares Outstanding | 1.57B | 1.57B | 1.93B | 3.13B | 3.15B | 3.15B | 3.14B | 3.16B | 3.21B | 3.2B |
| Basic Shares Outstanding | 1.56B | 1.56B | 1.92B | 3.11B | 3.12B | 3.13B | 3.1B | 3.13B | 3.21B | 3.16B |
| Dividend Payout Ratio | 123.27% | 75.92% | 131% | 638.73% | 75.36% | 123.3% | 88.14% | 199.34% | 280.28% | - |
TAK Balance Sheet
Takeda Pharmaceutical Company Limited (TAK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.26T | 1.08T | 3.05T | 2.47T | 2.71T | 2.59T | 2.4T | 2.56T | 2.52T | 3.12T |
| Cash & Short-Term Investments | 376.14B | 375.17B | 725.37B | 653.44B | 1T | 875B | 553.7B | 472.89B | 405.59B | 761.94B |
| Cash Only | 319.45B | 294.52B | 702.09B | 637.61B | 966.22B | 849.7B | 533.53B | 457.8B | 385.11B | 655.38B |
| Short-Term Investments | 56.68B | 80.65B | 23.28B | 15.82B | 36.6B | 25.3B | 20.17B | 15.09B | 20.48B | 107B |
| Accounts Receivable | 444.78B | 428.79B | 749.12B | 784.92B | 812.71B | 724.38B | 681.69B | 697.61B | 725.25B | 758.44B |
| Days Sales Outstanding | 93.73 | 88.4 | 130.38 | 87.05 | 92.76 | 74.08 | 61.78 | 59.72 | 57.78 | 58.29 |
| Inventory | 226.29B | 212.94B | 986.74B | 759.6B | 753.88B | 853.17B | 986.46B | 1.21T | 1.22T | 1.41T |
| Days Inventory Outstanding | 147.82 | 156.73 | 545.96 | 254.42 | 276.74 | 281.35 | 289.42 | 308.49 | 281.18 | 277.32 |
| Other Current Assets | 213.45B | 61.9B | 598.88B | 271.48B | 143.48B | 141.1B | 176.1B | 178.21B | 173B | 190.03B |
| Total Non-Current Assets | 3.09T | 3.03T | 10.8T | 10.35T | 10.2T | 10.58T | 11.56T | 12.55T | 11.73T | 12.3T |
| Property, Plant & Equipment | 530.15B | 536.8B | 1.32T | 1.39T | 1.45T | 1.58T | 1.69T | 1.99T | 1.97T | 2.09T |
| Fixed Asset Turnover | 3.27x | 3.30x | 1.59x | 2.37x | 2.20x | 2.25x | 2.38x | 2.14x | 2.33x | 2.24x |
| Goodwill | 1.02T | 1.03T | 4.16T | 4.01T | 4.03T | 4.41T | 4.79T | 5.41T | 5.32T | 5.76T |
| Intangible Assets | 1.07T | 1.01T | 4.86T | 4.17T | 3.91T | 3.82T | 4.27T | 4.27T | 3.63T | 3.52T |
| Long-Term Investments | 303.05B | 304.38B | 306.9B | 369.45B | 348.35B | 330.13B | 378.86B | 430.61B | 361.93B | 1.52T |
| Other Non-Current Assets | 54.41B | 77.98B | 87.47B | 103.85B | 100.34B | 82.61B | 63.33B | 51.21B | 70.28B | 287.22B |
| Total Assets | 4.36T▲ 0% | 4.11T▼ 5.7% | 13.87T▲ 237.8% | 12.82T▼ 7.6% | 12.91T▲ 0.7% | 13.18T▲ 2.1% | 13.96T▲ 5.9% | 15.11T▲ 8.2% | 14.25T▼ 5.7% | 15.42T▲ 0% |
| Asset Turnover | 0.40x | 0.43x | 0.15x | 0.26x | 0.25x | 0.27x | 0.29x | 0.28x | 0.32x | 0.31x |
| Asset Growth % | 13.9% | -5.72% | 237.82% | -7.58% | 0.71% | 2.06% | 5.92% | 8.25% | -5.7% | -18.03% |
| Total Current Liabilities | 1.37T | 737.51B | 2.51T | 2.18T | 1.77T | 2.15T | 2.48T | 2.31T | 2.51T | 2.61T |
| Accounts Payable | 240.62B | 133.71B | 212.35B | 211.63B | 232.1B | 295.93B | 307.45B | 319.95B | 308.45B | 467.91B |
| Days Payables Outstanding | 157.18 | 98.41 | 117.49 | 70.88 | 85.2 | 97.59 | 90.2 | 81.58 | 71.25 | 87.87 |
| Short-Term Debt | 545.03B | 18M | 984.95B | 586.82B | 22.15B | 203.99B | 339.6B | 367.25B | 548.94B | 583.55B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 509.86B | 429.54B | 1.09T | 1.09T | 1.26T | 1.22T | 1.26T | 1.29T | 1.35T | 1.41T |
| Current Ratio | 0.92x | 1.46x | 1.21x | 1.13x | 1.53x | 1.21x | 0.97x | 1.11x | 1.01x | 1.01x |
| Quick Ratio | 0.76x | 1.17x | 0.82x | 0.79x | 1.10x | 0.81x | 0.57x | 0.58x | 0.52x | 0.52x |
| Cash Conversion Cycle | 84.37 | 146.72 | 558.84 | 270.58 | 284.3 | 257.84 | 260.99 | 286.63 | 267.72 | 247.74 |
| Total Non-Current Liabilities | 1.04T | 1.35T | 6.2T | 5.92T | 5.96T | 5.35T | 5.12T | 5.52T | 4.81T | 5.16T |
| Long-Term Debt | 599.86B | 985.64B | 4.77T | 4.51T | 4.61T | 4.14T | 4.04T | 4.48T | 3.97T | 4.27T |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 153.4B | 90.72B | 721.46B | 710.15B | 542.85B | 451.51B | 270.62B | 113.78B | 35.15B | 133B |
| Other Non-Current Liabilities | 278.23B | 275.18B | 566.27B | 701.08B | 805.87B | 755.84B | 807.78B | 931.41B | 804.37B | 3.27T |
| Total Liabilities | 2.41T | 2.09T | 8.71T | 8.09T | 7.74T | 7.49T | 7.6T | 7.83T | 7.31T | 7.77T |
| Total Debt | 1.14T | 985.66B | 5.75T | 5.09T | 4.64T | 4.35T | 4.38T | 4.84T | 4.52T | 4.86T |
| Net Debt | 825.43B | 691.14B | 5.05T | 4.46T | 3.67T | 3.5T | 3.85T | 4.39T | 4.13T | 4.2T |
| Debt / Equity | 0.59x | 0.49x | 1.11x | 1.08x | 0.90x | 0.76x | 0.69x | 0.67x | 0.65x | 0.65x |
| Debt / EBITDA | 3.50x | 2.33x | 12.70x | 7.45x | 4.34x | 4.16x | 3.79x | 5.64x | 4.09x | 4.25x |
| Net Debt / EBITDA | 2.52x | 1.63x | 11.15x | 6.51x | 3.43x | 3.35x | 3.33x | 5.11x | 3.74x | 3.74x |
| Interest Coverage | 6.70x | 7.57x | 4.26x | 68.84x | 3.89x | 3.76x | 4.19x | 201.49x | 2.49x | 1.97x |
| Total Equity | 1.95T▲ 0% | 2.02T▲ 3.5% | 5.16T▲ 156.0% | 4.73T▼ 8.4% | 5.18T▲ 9.5% | 5.68T▲ 9.8% | 6.35T▲ 11.8% | 7.27T▲ 14.5% | 6.94T▼ 4.6% | 7.65T▲ 0% |
| Equity Growth % | -3.09% | 3.51% | 155.95% | -8.45% | 9.51% | 9.78% | 11.81% | 14.47% | -4.65% | -10.47% |
| Book Value per Share | 1239.98 | 1282.19 | 2670.19 | 1509.22 | 1645.08 | 1801.81 | 2023.95 | 2301.40 | 2160.26 | 2386.73 |
| Total Shareholders' Equity | 1.89T | 2T | 5.16T | 4.72T | 5.17T | 5.68T | 6.35T | 7.27T | 6.94T | 7.65T |
| Common Stock | 140.18B | 168.65B | 1.64T | 1.67T | 1.67T | 1.68T | 1.68T | 1.68T | 1.69T | 1.7T |
| Retained Earnings | 1.51T | 1.56T | 1.57T | 1.37T | 1.51T | 1.48T | 1.54T | 1.39T | 1.19T | 1.1T |
| Treasury Stock | -48.73B | -74.37B | -57.14B | -87.46B | -59.55B | -116.01B | -100.32B | -51.26B | -74.81B | -49.16B |
| Accumulated OCI | 291B | -4.79B | 349.88B | 92.56B | 366.11B | 934.17B | 1.51T | 2.51T | 2.35T | 3.15T |
| Minority Interest | 54.7B | 19.98B | 4.01B | 4B | 4.14B | 504M | 549M | 741M | 895M | 1.15B |
TAK Cash Flow Statement
Takeda Pharmaceutical Company Limited (TAK) cash flow — operating, investing & free cash flow history
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 261.36B | 377.85B | 328.48B | 669.75B | 1.01T | 1.12T | 977.16B | 716.34B | 1.06T | 1.06T |
| Operating CF Margin % | 15.09% | 21.34% | 15.66% | 20.35% | 31.61% | 31.47% | 24.26% | 16.8% | 23.07% | - |
| Operating CF Growth % | 925.31% | 44.57% | -13.07% | 103.89% | 50.94% | 11.1% | -13% | -26.69% | 47.58% | 34.67% |
| Net Income | 115.51B | 186.71B | 109.01B | 44.29B | 376.17B | 230.17B | 317.04B | 144.07B | 107.93B | 114.75B |
| Depreciation & Amortization | 222.79B | 182.13B | 272.45B | 583.65B | 559.67B | 583.15B | 664.4B | 728B | 761.4B | 750.47B |
| Stock-Based Compensation | 17.41B | 18.61B | 20.08B | 29.12B | 37.66B | 43.37B | 60.67B | 70.87B | 72.87B | 52.89B |
| Deferred Taxes | 27.83B | 30.5B | -14.12B | -105.04B | -9.94B | 72.41B | 58.05B | -91.41B | 0 | 66.25B |
| Other Non-Cash Items | 25.49B | -53.49B | -134.89B | 23.06B | -228.42B | 95.4B | -97.74B | 120.81B | 167.25B | 199.09B |
| Working Capital Changes | 29.68B | 13.4B | 75.95B | 94.67B | 275.78B | 98.61B | -25.26B | -256B | -52.25B | -7.71B |
| Change in Receivables | -37.31B | -647M | -13.38B | -34.83B | -9.32B | 127.29B | 75.13B | 15.1B | -58.96B | 12.09B |
| Change in Inventory | 3.89B | 13.72B | 58.68B | 137.49B | 25.98B | -46.15B | -79.16B | -115.74B | -34.97B | -86.56B |
| Change in Payables | 42.56B | 6.86B | -16.41B | -29.93B | 210.02B | 75.55B | -53.13B | -9.89B | 0 | 3.71B |
| Cash from Investing | -655.69B | -93.34B | -2.84T | 292.12B | 393.53B | -198.13B | -607.1B | -463.86B | -367.06B | -348.98B |
| Capital Expenditures | -112.03B | -128.26B | -134.11B | -217.71B | -236.47B | -186.04B | -633.69B | -175.42B | -200.79B | -367.84B |
| CapEx % of Revenue | 6.47% | 7.24% | 6.39% | 6.61% | 7.39% | 5.21% | 15.73% | 4.11% | 4.38% | - |
| Acquisitions | -524.74B | 56.75B | -2.87T | 456.66B | 530.39B | -21.48B | 7.96B | -4.74B | 0 | 32.41B |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -12.09B | 26.08B | 124.03B | 11.32B | 37.6B | 808M | 6.53B | -251.66B | -166.26B | -1.72B |
| Cash from Financing | 289.9B | -326.23B | 2.95T | -1.01T | -1.09T | -1.07T | -709.15B | -354.42B | -751.42B | -698.18B |
| Debt Issued (Net) | 471.42B | -153.14B | 3.16T | -586.09B | -511.46B | -600.48B | -285.07B | 1.51B | -314.31B | -512.55B |
| Equity Issued (Net) | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | 0 |
| Dividends Paid | -141.69B | -141.89B | -142.95B | -282.58B | -283.36B | -283.67B | -279.42B | -287.19B | -302.5B | -319.24B |
| Share Repurchases | -23.12B | -18.76B | -1.17B | -3.74B | -2.14B | -77.53B | -26.93B | -2.33B | -51.86B | -100.6B |
| Other Financing | -16.72B | -12.44B | -71.14B | -132.8B | -291.39B | -108.59B | -117.73B | -66.42B | -82.75B | 234.21B |
| Net Change in Cash | -131.97B▲ 0% | -46.73B▲ 64.6% | 407.12B▲ 971.2% | -65.11B▼ 116.0% | 328.61B▲ 604.7% | -116.53B▼ 135.5% | -316.17B▼ 171.3% | -75.73B▲ 76.0% | -72.69B▲ 4.0% | 118.96B▲ 0% |
| Free Cash Flow | 149.34B▲ 0% | 249.59B▲ 67.1% | 194.37B▼ 22.1% | 452.04B▲ 132.6% | 774.46B▲ 71.3% | 937.07B▲ 21.0% | 343.47B▼ 63.3% | 235.61B▼ 31.4% | 856.39B▲ 263.5% | 956.59B▲ 0% |
| FCF Margin % | 8.62% | 14.1% | 9.27% | 13.73% | 24.22% | 26.26% | 8.53% | 5.53% | 18.69% | 21.32% |
| FCF Growth % | 351.55% | 67.13% | -22.13% | 132.57% | 71.33% | 21% | -63.35% | -31.4% | 263.47% | 4.31% |
| FCF per Share | 95.01 | 158.63 | 100.51 | 144.31 | 246.09 | 297.07 | 109.39 | 74.55 | 266.73 | 266.73 |
| FCF Conversion (FCF/Net Income) | 2.27x | 2.02x | 3.01x | 15.14x | 2.69x | 4.88x | 3.08x | 4.97x | 9.80x | 8.34x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 112.98B | 34.88B |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TAK Key Ratios
Takeda Pharmaceutical Company Limited (TAK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 5.8% | 9.42% | 3.04% | 0.89% | 7.59% | 4.24% | 5.27% | 2.11% | 1.52% | 1.5% |
| Return on Invested Capital (ROIC) | 4.58% | 6.61% | 2.38% | 0.78% | 4.24% | 3.83% | 3.8% | 1.47% | 2.26% | 2.26% |
| Gross Margin | 67.74% | 71.99% | 68.54% | 66.89% | 68.91% | 68.99% | 69.11% | 66.43% | 65.51% | 62.11% |
| Net Margin | 6.64% | 10.56% | 5.2% | 1.34% | 11.76% | 6.45% | 7.87% | 3.38% | 2.36% | 2.56% |
| Debt / Equity | 0.59x | 0.49x | 1.11x | 1.08x | 0.90x | 0.76x | 0.69x | 0.67x | 0.65x | 0.65x |
| Interest Coverage | 6.70x | 7.57x | 4.26x | 68.84x | 3.89x | 3.76x | 4.19x | 201.49x | 2.49x | 1.97x |
| FCF Conversion | 2.27x | 2.02x | 3.01x | 15.14x | 2.69x | 4.88x | 3.08x | 4.97x | 9.80x | 8.34x |
| Revenue Growth | -4.17% | 2.22% | 18.45% | 56.93% | -2.84% | 11.61% | 12.85% | 5.87% | 7.45% | -2.03% |
TAK Frequently Asked Questions
Takeda Pharmaceutical Company Limited (TAK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Takeda Pharmaceutical Company Limited (TAK) reported $4.49T in revenue for fiscal year 2024. This represents a 366% increase from $963.48B in 2000.
Takeda Pharmaceutical Company Limited (TAK) grew revenue by 7.5% over the past year. This is steady growth.
Yes, Takeda Pharmaceutical Company Limited (TAK) is profitable, generating $114.75B in net income for fiscal year 2024 (2.4% net margin).
Dividend & Returns
Yes, Takeda Pharmaceutical Company Limited (TAK) pays a dividend with a yield of 3.61%. This makes it attractive for income-focused investors.
Takeda Pharmaceutical Company Limited (TAK) has a return on equity (ROE) of 1.5%. This is below average, suggesting room for improvement.
Takeda Pharmaceutical Company Limited (TAK) generated $956.59B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More TAK
Takeda Pharmaceutical Company Limited (TAK) financial analysis — history, returns, DCA and operating performance tools
Full TAK Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates